ProShares Ultra NASDAQ Biotechnology
29 hedge funds and large institutions have $42.3M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
Holders
29
Holders Change
+12
Holders Change %
+70.59%
% of All Funds
0.77%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.05%
New
15
Increased
9
Reduced
3
Closed
3
Calls
$5.97M
Puts
$13.6M
Net Calls
-$7.64M
Net Calls Change
+$1.55M
Top Buyers
| 1 |
AP
1
Advisors Preferred
Rockville,
Maryland
|
$7.6M |
| 2 |
2
Jane Street
New York
|
$5.05M |
| 3 |
TRCT
3
Tower Research Capital (TRC)
New York
|
$3.19M |
| 4 |
4
Morgan Stanley
New York
|
$1.73M |
| 5 |
ACP
5
Aviance Capital Partners
Naples,
Florida
|
$682K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | -$13K | -200 | -50% |
|
|
SSG
27
Summit Securities Group
New York
| $13K | +$13K | +200 | New |
|
|
TCM
28
Tradewinds Capital Management
Bellingham,
Washington
| $1K | +$1K | +20 | New |
|
29
Verition Fund Management
Greenwich,
Connecticut
| – | -$740K | -14,228 | Closed |
|
|
FTUS
30
Flow Traders U.S.
New York
| – | -$662K | -12,730 | Closed |
|
|
BCM
31
Blume Capital Management
Berkeley,
California
| – | -$31K | -600 | Closed |
|